DS
BMRN icon

DRW Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

DRW Securities’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,900
Closed -$865K – 535
2024
Q1 		$865K Buy
+9,900
New +$886K 0.02% 188

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DRW Securities's BMRN Position: Q1 2026 in Review

DRW Securities increased its BioMarin Pharmaceuticals (BMRN) stake by 142% in Q1 2026, buying an estimated $425K and bringing the position to 12,426 shares worth $702K. The position accounts for 0.01% of the portfolio, ranked #461.

DRW Securities first reported a position in BMRN in Q1 2024 and has held it in 5 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • DRW Securities held 12,426 shares of BioMarin Pharmaceuticals worth $702K as of Q1 2026.
  • DRW Securities bought 7,288 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $425K.
  • BioMarin Pharmaceuticals made up 0.01% of DRW Securities's portfolio in Q1 2026, its #461 holding.
  • DRW Securities first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.